Oncopeptides is listed on Nasdaq Stockholm Small Cap under the trade symbol ONCO, since February 22, 2017.
The information is delayed by 15 minutes.
This share price calculator will determine your shares’ value in SEK.
Analysts that follow Oncopeptides.
Georg Tigalonov-Bjerke
Phone: +47 22 01 60 00
E-mail: Georg.Tigalonov-Bjerke@abgsc.no
Erik Hultgård
Phone: +46 (0)8 5886 9237
E-mail: erik.hultgard@carnegie.se
Richard Ramanius
Phone: +46 79 006 8798
E-mail: richard.ramanius@redeye.se
Oncopeptides will continue to focus on further developing and expanding the company’s project portfolio. Available financial resources and the reported results shall therefore be reinvested in the business to finance the company’s long-term strategy. The board’s intention is not to propose a dividend to shareholders before the company is able to generate long-term sustainable profitability.
Any future dividends and the size thereof will be determined on the basis of the company’s long-term growth, earnings trend and capital requirements, taking into account the current objectives and strategies adopted. Dividends shall, in so far as dividends are proposed, be well-balanced with respect to the company’s targets, scope and risk.
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care